G R Pettit, M R Rhodes, D L Herald, D J Chaplin, M R Stratford, E Hamel, R K Pettit, J C Chapuis, D Oliva
{"title":"抗肿瘤药物康布他汀A-4前药反式异构体的合成。","authors":"G R Pettit, M R Rhodes, D L Herald, D J Chaplin, M R Stratford, E Hamel, R K Pettit, J C Chapuis, D Oliva","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>The (E)-stilbene isomer (2a) of the (Z)-combretastatin A-4 prodrug (1b) was efficiently prepared from (E)-combretastatin A-4 by a reaction sequence employing phosphorylation (dibenzyl chlorophosphite), cleavage (trimethyliodosilane) of the benzyl ester and reaction of the resulting phosphoric acid with sodium methoxide. The sodium phosphate product (2c) was also found to be an important side-product, presumably from iodine-catalyzed isomerization, when the analogous synthetic route was used to obtain the combretastatin A-4 prodrug (1b). The phosphoric acid precursor of prodrug 1b derived from (Z)-combretastatin A-4 (1a) was converted into a series of metal cation and ammonium cation salts to evaluate effects on human cancer cell growth, antimicrobial activities and solubility behavior.</p>","PeriodicalId":7927,"journal":{"name":"Anti-cancer drug design","volume":"13 8","pages":"981-93"},"PeriodicalIF":0.0000,"publicationDate":"1998-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Antineoplastic agents 393. Synthesis of the trans-isomer of combretastatin A-4 prodrug.\",\"authors\":\"G R Pettit, M R Rhodes, D L Herald, D J Chaplin, M R Stratford, E Hamel, R K Pettit, J C Chapuis, D Oliva\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>The (E)-stilbene isomer (2a) of the (Z)-combretastatin A-4 prodrug (1b) was efficiently prepared from (E)-combretastatin A-4 by a reaction sequence employing phosphorylation (dibenzyl chlorophosphite), cleavage (trimethyliodosilane) of the benzyl ester and reaction of the resulting phosphoric acid with sodium methoxide. The sodium phosphate product (2c) was also found to be an important side-product, presumably from iodine-catalyzed isomerization, when the analogous synthetic route was used to obtain the combretastatin A-4 prodrug (1b). The phosphoric acid precursor of prodrug 1b derived from (Z)-combretastatin A-4 (1a) was converted into a series of metal cation and ammonium cation salts to evaluate effects on human cancer cell growth, antimicrobial activities and solubility behavior.</p>\",\"PeriodicalId\":7927,\"journal\":{\"name\":\"Anti-cancer drug design\",\"volume\":\"13 8\",\"pages\":\"981-93\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1998-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Anti-cancer drug design\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anti-cancer drug design","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
以(E)-combretastatin a -4为原料,经磷酸化(二苄氯亚磷酸酯)、裂解(三甲基碘硅烷)、磷酸与甲氧基钠反应,制备了(Z)-combretastatin a -4前药(1b)的(E)-二苯乙烯异构体(2a)。磷酸钠产物(2c)也被发现是一个重要的副产物,可能来自于碘催化异构化,当类似的合成路线用于获得combretastatin A-4前药(1b)时。将(Z)-combretastatin a -4 (1a)衍生的前药1b磷酸前体转化为一系列金属阳离子和铵阳离子盐,评价其对人癌细胞生长、抗菌活性和溶解度的影响。
Antineoplastic agents 393. Synthesis of the trans-isomer of combretastatin A-4 prodrug.
The (E)-stilbene isomer (2a) of the (Z)-combretastatin A-4 prodrug (1b) was efficiently prepared from (E)-combretastatin A-4 by a reaction sequence employing phosphorylation (dibenzyl chlorophosphite), cleavage (trimethyliodosilane) of the benzyl ester and reaction of the resulting phosphoric acid with sodium methoxide. The sodium phosphate product (2c) was also found to be an important side-product, presumably from iodine-catalyzed isomerization, when the analogous synthetic route was used to obtain the combretastatin A-4 prodrug (1b). The phosphoric acid precursor of prodrug 1b derived from (Z)-combretastatin A-4 (1a) was converted into a series of metal cation and ammonium cation salts to evaluate effects on human cancer cell growth, antimicrobial activities and solubility behavior.